Ignoring Liver Health in the EU's NCD Strategy: A Costly Oversight
The EU's ambitious Healthier Together initiative aims to tackle non-communicable diseases (NCDs), but is it missing a crucial piece of the puzzle? As the program enters its final phase, experts raise concerns about the lack of focus on liver health, a key player in metabolic health.
The 2022-2027 framework provides a comprehensive approach to various NCDs, but surprisingly, liver disease is not explicitly addressed, despite its strong connection to obesity and type 2 diabetes. This omission was highlighted during a policy discussion, where specialists labeled it a structural weakness in the EU's NCD strategy.
But here's where it gets controversial: Cyrielle Caussy, a renowned professor, argues that the liver is the 'blind spot' in the EU's health agenda. She emphasizes that the liver is a central organ in glucose, lipid, and energy metabolism, directly linked to major NCDs. Yet, Steatotic Liver Disease (SLD) affects a significant portion of the global population and remains largely unnoticed in EU health strategies.
Obesity: A Misunderstood Epidemic
The discussion delves into the root of the problem—the misunderstanding of obesity. Experts clarify that obesity is not solely about weight but is an adipose tissue disease, characterized by excess and dysfunction of body fat. This misunderstanding leads to a lack of recognition, perpetuating stigma and hindering effective treatment.
GLP-1 Medicines: A Double-Edged Sword?
While new GLP-1 drugs show promise in treating diabetes, fatty liver, and cardiovascular disease, access is limited due to lack of reimbursement. This raises concerns about equity, as those who need these medicines the most may not be able to afford them. Moreover, Dr. Kremlin Wickramasinghe warns that these drugs might distract from political action on prevention, a crucial aspect of healthcare.
Early Detection: A Cost-Effective Solution
The good news is that early detection of advanced liver disease is feasible and cost-effective. Experts recommend the FIB-4 score as an initial test, followed by more accurate assessments like trans-elastography and blood tests. However, public awareness and simplified pathways are essential to ensure the right patients receive the necessary care.
The Prevention Gap
Dr. Wickramasinghe points out that Europe's prevention gap starts long before screening. Despite NCD risk factors causing 80% of deaths, there is a lack of communication with patients about these factors. Stigma and discrimination further complicate matters, making it challenging to discuss prevention with patients.
EU Policy: Underutilized Powers
MEP Tomislav Sokol criticizes the EU's slow action on nutrition labelling and other health-related policies. He argues that the EU's powers in labelling, marketing, prevention, and pharmaceutical reform are not being fully utilized, and the long-term benefits are not evident to most politicians.
A Call for Political Courage
As the Healthier Together initiative nears its conclusion, experts agree that the EU must confront political and commercial pressures to effectively address NCDs. Europe has the evidence and solutions, but political courage is needed to implement them. Will the EU rise to the challenge and turn the tide on NCDs, or will these diseases continue to burden its citizens?
The article highlights a critical aspect of healthcare strategy, showing that even well-intentioned initiatives can have blind spots. Do you think the EU's approach to NCDs is on the right track? Are there other aspects of metabolic health that should be prioritized? Share your thoughts and let's explore the complexities of public health policy together.
